SK62003A3 - A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents
A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes Download PDFInfo
- Publication number
- SK62003A3 SK62003A3 SK6-2003A SK62003A SK62003A3 SK 62003 A3 SK62003 A3 SK 62003A3 SK 62003 A SK62003 A SK 62003A SK 62003 A3 SK62003 A3 SK 62003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- alkyl
- aryl
- hydrogen
- alicyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21653100P | 2000-07-06 | 2000-07-06 | |
| PCT/US2001/021557 WO2002003978A2 (en) | 2000-07-06 | 2001-07-05 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK62003A3 true SK62003A3 (en) | 2003-09-11 |
Family
ID=22807416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK6-2003A SK62003A3 (en) | 2000-07-06 | 2001-07-05 | A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1372660A2 (ru) |
| JP (1) | JP2004508297A (ru) |
| KR (1) | KR100854851B1 (ru) |
| CN (2) | CN100396283C (ru) |
| AU (2) | AU2001273271B2 (ru) |
| BR (1) | BR0112212A (ru) |
| CA (1) | CA2412142A1 (ru) |
| CZ (1) | CZ20035A3 (ru) |
| HU (1) | HUP0301830A3 (ru) |
| IL (2) | IL153513A0 (ru) |
| MX (1) | MXPA02012713A (ru) |
| NO (1) | NO20030034L (ru) |
| NZ (1) | NZ523227A (ru) |
| PL (1) | PL365779A1 (ru) |
| RU (1) | RU2328308C2 (ru) |
| SK (1) | SK62003A3 (ru) |
| WO (1) | WO2002003978A2 (ru) |
| ZA (1) | ZA200300044B (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| JP2002524463A (ja) | 1998-09-09 | 2002-08-06 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター |
| AU2001245532B2 (en) | 2000-03-08 | 2005-08-11 | Metabasis Therapeutics, Inc. | Novel aryl fructose-1,6-bisphosphatase inhibitors |
| NZ532427A (en) | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| AU2003201998C1 (en) | 2002-01-10 | 2012-10-25 | Imperial Innovations Limited | Modification of feeding behavior |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| EA013249B1 (ru) | 2003-12-26 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Производные тиазола |
| US20070225259A1 (en) * | 2004-08-18 | 2007-09-27 | Qun Dang | Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase |
| TW200633720A (en) * | 2004-12-13 | 2006-10-01 | Sankyo Co | Medicinal composition for diabetic |
| TW200738245A (en) * | 2005-08-22 | 2007-10-16 | Sankyo Co | Pharmaceutical composition containing FBPase inhibitor |
| WO2007129522A1 (ja) * | 2006-04-10 | 2007-11-15 | Daiichi Sankyo Company, Limited | 乾式製造法製剤 |
| US20100222304A1 (en) | 2006-11-02 | 2010-09-02 | Lillian W Chiang | Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| UY35065A (es) * | 2012-10-08 | 2014-05-30 | Lg Life Sciences Ltd | Fármaco combinado que comprende gemigliptina y metformina y método para su preparación |
| CN104788350A (zh) * | 2014-01-22 | 2015-07-22 | 天津大学 | 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法 |
| CN106831437B (zh) * | 2016-02-03 | 2019-06-21 | 华中师范大学 | 含硝基乙烯基的酯类化合物及其制备方法和应用 |
| CN114907285B (zh) * | 2021-02-10 | 2023-09-22 | 华中师范大学 | 酰化糖精类化合物及其制备方法和应用、降血糖药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2008325A1 (en) * | 1989-01-24 | 1990-07-24 | Harry E. Gruber | Method and compounds for aica riboside delivery and for lowering blood glucose |
| AU6452098A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| PT970095E (pt) * | 1997-03-07 | 2004-03-31 | Metabasis Therapeutics Inc | Novos inibidores benzimidazole de frutose-1,6-bisfosfatase |
| AU6691798A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU3087099A (en) * | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
| JP2002524463A (ja) * | 1998-09-09 | 2002-08-06 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター |
| CN101164618A (zh) * | 1998-12-24 | 2008-04-23 | 症变治疗公司 | 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合 |
| PT1248604E (pt) * | 2000-01-21 | 2007-01-31 | Novartis Ag | Associações compreendendo inibidor de dipeptidilpeptidase-iv |
| GB0015627D0 (en) * | 2000-06-26 | 2000-08-16 | Rademacher Group Limited | Phosphoglycan messengers and their medical uses |
-
2001
- 2001-07-05 BR BR0112212-6A patent/BR0112212A/pt not_active IP Right Cessation
- 2001-07-05 CN CNB018149243A patent/CN100396283C/zh not_active Expired - Fee Related
- 2001-07-05 NZ NZ523227A patent/NZ523227A/en not_active IP Right Cessation
- 2001-07-05 HU HU0301830A patent/HUP0301830A3/hu unknown
- 2001-07-05 AU AU2001273271A patent/AU2001273271B2/en not_active Ceased
- 2001-07-05 PL PL01365779A patent/PL365779A1/xx unknown
- 2001-07-05 MX MXPA02012713A patent/MXPA02012713A/es not_active Application Discontinuation
- 2001-07-05 IL IL15351301A patent/IL153513A0/xx unknown
- 2001-07-05 CA CA002412142A patent/CA2412142A1/en not_active Abandoned
- 2001-07-05 JP JP2002508433A patent/JP2004508297A/ja active Pending
- 2001-07-05 RU RU2003103436/15A patent/RU2328308C2/ru not_active IP Right Cessation
- 2001-07-05 EP EP01952530A patent/EP1372660A2/en not_active Withdrawn
- 2001-07-05 SK SK6-2003A patent/SK62003A3/sk unknown
- 2001-07-05 CN CNA200810098112XA patent/CN101301294A/zh active Pending
- 2001-07-05 AU AU7327101A patent/AU7327101A/xx active Pending
- 2001-07-05 CZ CZ20035A patent/CZ20035A3/cs unknown
- 2001-07-05 WO PCT/US2001/021557 patent/WO2002003978A2/en active IP Right Grant
- 2001-07-05 KR KR1020037000126A patent/KR100854851B1/ko active IP Right Grant
-
2002
- 2002-12-18 IL IL153513A patent/IL153513A/en not_active IP Right Cessation
-
2003
- 2003-01-02 ZA ZA200300044A patent/ZA200300044B/en unknown
- 2003-01-03 NO NO20030034A patent/NO20030034L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN100396283C (zh) | 2008-06-25 |
| CN1599612A (zh) | 2005-03-23 |
| HUP0301830A2 (hu) | 2003-11-28 |
| CA2412142A1 (en) | 2002-01-17 |
| BR0112212A (pt) | 2003-12-30 |
| IL153513A0 (en) | 2003-07-06 |
| NO20030034D0 (no) | 2003-01-03 |
| ZA200300044B (en) | 2004-05-06 |
| KR20030031952A (ko) | 2003-04-23 |
| RU2328308C2 (ru) | 2008-07-10 |
| AU7327101A (en) | 2002-01-21 |
| CZ20035A3 (cs) | 2003-05-14 |
| NO20030034L (no) | 2003-03-05 |
| PL365779A1 (en) | 2005-01-10 |
| WO2002003978A2 (en) | 2002-01-17 |
| WO2002003978A3 (en) | 2003-10-16 |
| NZ523227A (en) | 2005-04-29 |
| AU2001273271B2 (en) | 2006-01-05 |
| JP2004508297A (ja) | 2004-03-18 |
| HUP0301830A3 (en) | 2007-10-29 |
| EP1372660A2 (en) | 2004-01-02 |
| IL153513A (en) | 2014-07-31 |
| MXPA02012713A (es) | 2004-09-10 |
| KR100854851B1 (ko) | 2008-08-27 |
| CN101301294A (zh) | 2008-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090197836A1 (en) | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | |
| KR100854851B1 (ko) | 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물 | |
| ES2246586T3 (es) | Una combinacion de inhibidores de fbpasa y sensibilizantes de insulina para el tratamiento de la diabetes. | |
| US20080004226A1 (en) | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | |
| CN101827832B (zh) | 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用 | |
| AU2001273271A1 (en) | A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | |
| SK8892002A3 (en) | Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof | |
| NZ510209A (en) | Method for treating diabetes, insulin resistance, hyperglycaemia, elevated fatty acids, or hypertriglyceridemia with an aP2 inhibitor in combination with another antidiabetic agent | |
| AU2006265653A1 (en) | Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer | |
| AU2006201410A1 (en) | A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | |
| EP1552850A2 (en) | A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | |
| ERION | QUN DANG*, PAUL D. VAN POELJE AND |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB9A | Suspension of patent application procedure |